Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) — Cash Flow Reinvestment Rate
Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) has a Cash Flow Reinvestment Rate of 0.19x as of September 2025, reinvesting CN¥21.06 Million (capex CN¥21.06 Million ) from operating cash flow of CN¥110.78 Million. See Tianjin Zhongxin Pharmaceutical Group Co free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Cash Flow Reinvestment Rate (2001–2024)
Historical reinvestment intensity for Tianjin Zhongxin Pharmaceutical Group Corp Ltd across 22 annual periods. For the full cash flow conversion analysis, see Tianjin Zhongxin Pharmaceutical Group Co cash conversion from operations.
Annual Cash Flow Reinvestment Rate for Tianjin Zhongxin Pharmaceutical Group Corp Ltd (2001–2024)
Year-by-year capital reinvestment analysis for Tianjin Zhongxin Pharmaceutical Group Corp Ltd. See Tianjin Zhongxin Pharmaceutical Group Co (600329) financial flexibility to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.00x | CN¥925.65 Million | CN¥924.67 Million | CN¥117.81 Million | ▼ -2.9% |
| 2023 | 1.03x | CN¥709.84 Million | CN¥688.49 Million | CN¥140.93 Million | ▲ +481.0% |
| 2022 | 0.18x | CN¥120.18 Million | CN¥677.25 Million | CN¥107.90 Million | ▼ -69.2% |
| 2021 | 0.58x | CN¥491.87 Million | CN¥852.40 Million | CN¥156.95 Million | ▲ +68.3% |
| 2020 | 0.34x | CN¥230.21 Million | CN¥671.42 Million | CN¥189.16 Million | ▼ -44.1% |
| 2019 | 0.61x | CN¥303.67 Million | CN¥495.49 Million | CN¥205.61 Million | ▼ -62.9% |
| 2018 | 1.65x | CN¥578.87 Million | CN¥350.14 Million | CN¥175.81 Million | ▲ +239.1% |
| 2016 | 0.49x | CN¥204.73 Million | CN¥419.90 Million | CN¥116.20 Million | ▼ -61.6% |
| 2015 | 1.27x | CN¥457.26 Million | CN¥360.58 Million | CN¥92.64 Million | ▲ +418.5% |
| 2014 | 0.24x | CN¥70.15 Million | CN¥286.85 Million | CN¥70.15 Million | ▼ -27.9% |
| 2013 | 0.34x | CN¥72.42 Million | CN¥213.44 Million | CN¥72.42 Million | ▼ -82.9% |
| 2012 | 1.98x | CN¥41.18 Million | CN¥20.81 Million | CN¥41.18 Million | ▲ +699.8% |
| 2011 | 0.25x | CN¥43.02 Million | CN¥173.88 Million | CN¥43.02 Million | ▼ -50.0% |
| 2010 | 0.49x | CN¥68.79 Million | CN¥139.04 Million | CN¥68.79 Million | ▼ -52.4% |
| 2009 | 1.04x | CN¥86.74 Million | CN¥83.41 Million | CN¥86.74 Million | ▲ +322.2% |
| 2008 | 0.25x | CN¥38.36 Million | CN¥155.77 Million | CN¥38.36 Million | ▼ -90.8% |
| 2007 | 2.67x | CN¥53.74 Million | CN¥20.13 Million | CN¥53.74 Million | ▲ +366.7% |
| 2005 | 0.57x | CN¥149.80 Million | CN¥261.91 Million | CN¥149.80 Million | ▼ -97.6% |
| 2004 | 24.04x | CN¥252.31 Million | CN¥10.50 Million | CN¥252.31 Million | ▲ +212.4% |
| 2003 | 7.70x | CN¥589.20 Million | CN¥76.57 Million | CN¥589.20 Million | ▲ +700.3% |
| 2002 | 0.96x | CN¥180.40 Million | CN¥187.60 Million | CN¥180.40 Million | ▲ +13.2% |
| 2001 | 0.85x | CN¥133.95 Million | CN¥157.73 Million | CN¥133.95 Million | — |